Anti-Human Cytokeratin 19 FITC

Description: This BA17 monoclonal antibody reacts with human cytokeratin 19 (CK19), a 44-kDa type I (acidic) intermediate filament protein that lacks the non-alpha-helical tail domain present in other keratins. Cytokeratins form the intracellular cytoskeletal network that maintains the integrity and stability of cells and tissues. Cytokeratin 19 is expressed in a wide variety of simple and stratified epithelial tissue. Moreover, cytokeratin 19 expression can be induced by vitamin A, SV40 transformation, and cancer. A soluble form of cytokeratin 19 generated by caspase 3 cleavage has also been found to be secreted by cancer cells, thus possibly indicating tumor metastasis. Cytokeratin 19 often exists as a heterodimer with cytokeratin 7, a type II keratin.

References: Alix-Panabières C, Vendrell JP, Slijper M, Pellé O, Barbotte E, Mercier G, Jacot W, Fabbro M, Pantel K. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res. 2009;11(3):R39.

Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol. 2008 Jun;129(6):705-33.

Bártek J, Bártková J, Taylor-Papadimitriou J, Rejthar A, Kovarík J, Lukás Z, Vojtesek B. Differential expression of keratin 19 in normal human epithelial tissues revealed by monospecific monoclonal antibodies. Histochem J. 1986 Oct;18(10):565-75. (BA17, IHC)

Bader BL, Magin TM, Hatzfeld M, Franke WW. Amino acid sequence and gene organization of cytokeratin no. 19, an exceptional tail-less intermediate filament protein. EMBO J. 1986 Aug;5(8):1865-75.